Cardiac Arrhythmia Center Cardiovascular Division University of Minnesota Minneapolis MN.
Hospital of the Good Samaritan Los Angeles CA.
J Am Heart Assoc. 2021 Sep 7;10(17):e021002. doi: 10.1161/JAHA.121.021002. Epub 2021 Aug 16.
Background Recently there has been increased interest in a possible association between mast cell activation (MCA) disorder and postural orthostatic tachycardia syndrome (POTS). This study examined the frequency with which symptoms and laboratory findings suggesting MCA disorder occurred in patients diagnosed with POTS. Methods and Results Data were obtained from patients in whom symptoms and orthostatic testing were consistent with a POTS diagnosis. Individuals with <4 months symptom duration, evident ongoing inflammatory disease, suspected volume depletion, or declined consent were excluded. All patients had typical POTS symptoms; some, however, had additional nonorthostatic complaints not usually associated with POTS. The latter patients underwent additional testing for known MCA biochemical mediators including prostaglandins, histamine, methylhistamine, and plasma tryptase. The study comprised 69 patients who met POTS diagnostic criteria. In 44 patients (44/69, 64%) additional nonorthostatic symptoms included migraine, allergic complaints, skin rash, or gastrointestinal symptoms. Of these 44 patients, 29 (66%) exhibited at least 1 laboratory abnormality suggesting MCA disorder, and 11/29 patients had 2 or more such abnormalities. Elevated prostaglandins (n=16) or plasma histamine markers (n=23) were the most frequent findings. Thus, 42% (29/69) of patients initially diagnosed with POTS exhibited both additional symptoms and at least 1 elevated biochemical marker suggesting MCA disorder. Conclusions Laboratory findings suggesting MCA disorder were relatively common in patients diagnosed with POTS and who present with additional nonorthostatic gastrointestinal, cutaneous, and allergic symptoms. While solitary abnormal laboratory findings are not definitive, they favor MCA disorder being considered in such cases.
近来,人们对肥大细胞激活(MCA)障碍与体位性心动过速综合征(POTS)之间可能存在关联的兴趣日益增加。本研究检查了在诊断为 POTS 的患者中,出现提示 MCA 障碍的症状和实验室发现的频率。
从症状和直立测试与 POTS 诊断一致的患者中获取数据。排除症状持续时间<4 个月、明显持续存在炎症性疾病、疑似容量不足或拒绝同意的个体。所有患者均有典型的 POTS 症状;然而,有些患者还有其他通常与 POTS 无关的非直立性投诉。这些患者接受了其他测试,以检查已知的 MCA 生化介质,包括前列腺素、组胺、甲基组氨酸和血浆胰蛋白酶原。该研究包括 69 名符合 POTS 诊断标准的患者。在 44 名患者(44/69,64%)中,有额外的非直立性症状,包括偏头痛、过敏投诉、皮疹或胃肠道症状。在这 44 名患者中,有 29 名(66%)至少有 1 项实验室异常提示 MCA 障碍,而 11/29 名患者有 2 项或更多此类异常。升高的前列腺素(n=16)或血浆组胺标志物(n=23)是最常见的发现。因此,最初诊断为 POTS 的 69 名患者中有 42%(29/69)同时存在其他症状和至少 1 项升高的生化标志物提示 MCA 障碍。
在诊断为 POTS 且出现额外非直立性胃肠道、皮肤和过敏症状的患者中,提示 MCA 障碍的实验室发现相对常见。虽然孤立的异常实验室发现并不确定,但它们支持在这些情况下考虑 MCA 障碍。